Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Detail (Tables)

v3.8.0.1
Condensed Consolidated Financial Statements Detail (Tables)
9 Months Ended
Sep. 30, 2017
Condensed Consolidated Financial Statements Detail [Abstract]  
Trade and Other Receivables

Trade and other receivables consisted of the following (in thousands):

 

 

September 30,

 

 

December 31,

 

 

 

2017

 

 

2016

 

Trade receivables, net

 

$

913

 

 

$

474

 

Other receivables

 

 

113

 

 

 

92

 

Trade and other receivables, net

 

$

1,026

 

 

$

566

 

 

Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

 

 

September 30,

 

 

December 31,

 

 

 

2017

 

 

2016

 

Equipment and furniture

 

$

722

 

 

$

14,023

 

Leasehold improvements

 

 

334

 

 

 

554

 

 

 

 

1,056

 

 

 

14,577

 

Less: Accumulated depreciation and amortization

 

 

(959

)

 

 

(13,541

)

Property and equipment, net

 

$

97

 

 

$

1,036

 

 

Accrued and Other Liabilities

Accrued and other liabilities consisted of the following (in thousands):

 

 

 

September 30,

 

 

December 31,

 

 

 

2017

 

 

2016

 

Accrued payroll and other benefits

 

$

151

 

 

$

1,582

 

Accrued clinical trial costs

 

 

 

 

 

458

 

Accrued incentive compensation

 

 

396

 

 

 

 

Accrued legal and accounting fees

 

 

231

 

 

 

385

 

Deferred rent

 

 

746

 

 

 

707

 

Other

 

 

77

 

 

 

1,083

 

Total

 

$

1,601

 

 

$

4,215

 

 

Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Income (Loss) Per Share Available to Common Stockholders

The following is a reconciliation of the numerator (net income or loss) and the denominator (number of shares) used in the calculation of basic and diluted net income (loss) per share available to common stockholders (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2017

 

 

2016

 

 

2017

 

 

2016

 

Numerator

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

26,344

 

 

$

(12,525

)

 

$

15,915

 

 

$

(36,050

)

Less: Deemed dividend on convertible preferred stock

 

 

 

 

 

 

 

 

(5,603

)

 

 

 

Less: Allocation of undistributed earnings to participating securities

 

 

(10,306

)

 

 

 

 

 

(3,703

)

 

 

 

Net income (loss) available to common stockholders, basic

 

$

16,038

 

 

$

(12,525

)

 

$

6,609

 

 

$

(36,050

)

Adjustments to undistributed earnings allocated to participating securities

 

 

380

 

 

 

 

 

 

60

 

 

 

 

Net income (loss) available to common stockholders, diluted

 

$

16,418

 

 

$

(12,525

)

 

$

6,669

 

 

$

(36,050

)

Denominator

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding used for basic net income (loss) per share available to common stockholders

 

 

7,786

 

 

 

6,029

 

 

 

7,424

 

 

 

6,010

 

Effect of dilutive stock options

 

 

489

 

 

 

 

 

 

193

 

 

 

 

Weighted average shares outstanding used for diluted net income (loss) per share available to common stockholders

 

 

8,275

 

 

 

6,029

 

 

 

7,617

 

 

 

6,010

 

 

Outstanding Securities Considered Anti-Dilutive

Potentially dilutive securities are excluded from the calculation of diluted net income (loss) per share available to common stockholders if their inclusion is anti-dilutive. The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net income (loss) per share available to common stockholders (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2017

 

 

2016

 

 

2017

 

 

2016

 

Convertible preferred stock (as converted)

 

 

 

 

 

 

 

 

4,160

 

 

 

 

Common stock options and RSUs

 

 

313

 

 

 

558

 

 

 

753

 

 

 

549

 

Warrants for common stock

 

 

19

 

 

 

917

 

 

 

139

 

 

 

915

 

Total

 

 

332

 

 

 

1,475

 

 

 

5,052

 

 

 

1,464